Investor Presentaiton
CSL112 Apolipoprotein A-I (human) - AEGIS-II
Objective: to evaluate the efficacy and safety of CSL112 on reducing the risk of
cardiovascular (CV) death, myocardial infarction (MI), or stroke
Treatment period
(4 weekly infusions)
6 g CSL112 (n=9,112)
Follow-up period (1 year)
18,219 MI patients
from
49 Countries
Infusion:
Placebo (n=9,107)
1
2
3
2
3
4
5
6
7
8
9
10
11
8
15
22
29
60
90
180
270
365
Visit:
1
Study day:
Within 5 days of
arriving for evaluation
and treatment of MI
Randomization
Driven by Our Promise
11
All infusions given within
30 days of the first infusion
Primary Endpoint
at 90 days
Time to first occurrence of any component of the
composite endpoint of CV death, MI, or stroke from
time of randomization through 90 days
CSLView entire presentation